Center-Authored Papers

Filters: Author is Blum, Kristie A  [Clear All Filters]
Journal Article
Nowakowski GS, Blum KA, Kahl BS, Friedberg JW, Baizer L, Little RF, Maloney DG, Sehn LH, Williams ME, Wilson WH et al..  2016.  Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.. Journal of the National Cancer Institute. 108(12) Abstract
Salles G, Schuster SJ, de Vos S, Wagner-Johnston ND, Viardot A, Blum KA, Flowers CR, Jurczak WJ, Flinn IW, Kahl BS et al..  2016.  Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study.. Haematologica.
Evens AM, Kanakry JA, Sehn LH, Kritharis A, Feldman T, Kroll A, Gascoyne RD, Abramson JS, Petrich AM, Hernandez-Ilizaliturri FJ et al..  2015.  Gray zone lymphoma with features intermediate between classical hodgkin lymphoma and diffuse large B-cell lymphoma: Characteristics, outcomes, and prognostication among a large multicenter cohort.. American journal of hematology. Abstract
Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Benitez CM, Bernat K, Bierman PJ, Blum KA et al..  2017.  Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.. Journal of the National Comprehensive Cancer Network : JNCCN. 15(5):608-638. Abstract
Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Bierman PJ, Blum KA, Chen R, Dabaja B et al..  2012.  Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines.. Journal of the National Comprehensive Cancer Network : JNCCN. 10(5):589-597. Abstract
Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Benitez CM, Bierman PJ, Blum KA, Chen R et al..  2015.  Hodgkin lymphoma, version 2.2015.. Journal of the National Comprehensive Cancer Network : JNCCN. 13(5):554-86. Abstract
Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Bello CM, Bierman PJ, Blum KA, Dabaja B, Duron Y, Forero A et al..  2011.  Hodgkin lymphoma.. Journal of the National Comprehensive Cancer Network : JNCCN. 9(9):1020-58.
Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, Shah KA, Whyman JD, Lansigan F, Hernandez-Ilizaliturri FJ et al..  2014.  Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.. Blood. 124(15):2354-61. Abstract
Evens AM, Advani R, Press OW, Lossos IS, Vose JM, Hernandez-Ilizaliturri FJ, Robinson BK, Otis S, Nadav Dagan L, Abdallah R et al..  2013.  Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(32):4132-9. Abstract
Landsburg DJ, Falkiewicz MK, Maly J, Blum KA, Howlett C, Feldman T, Mato AR, Hill BT, Li S, Medeiros JL et al..  2017.  Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. :JCO2017722157. Abstract
Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A et al..  2014.  PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma.. The New England journal of medicine. Abstract
Chen RW, Li H, Bernstein SH, Kahwash S, Rimsza LM, Forman SJ, Constine L, Shea TC, Cashen AF, Blum KA et al..  2016.  RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106.. British journal of haematology. Abstract
Landsburg DJ, Falkiewicz MK, Petrich AM, Chu BA, Behdad A, Li S, Medeiros JL, Cassaday RD, Reddy NM, Bast MA et al..  2016.  Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.. British journal of haematology. 175(4):631-640. Abstract
Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih C-J, Williams MP, Shaffer AL, Gerecitano J et al..  2015.  Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.. Nature medicine. Abstract